Features | Partner Sites | Information | LinkXpress
Sign In
GLOBETECH PUBLISHING LLC
GLOBETECH PUBLISHING LLC
PURITAN MEDICAL

NMR Spectroscopy Nature Bank Creates Limitless Opportunities for Drug Discovery

By BiotechDaily International staff writers
Posted on 28 Apr 2014
Australian researchers have developed a new tool for finding natural compounds that could form the foundation of innovative therapeutic agents. 

The corresponding author, Prof. Ronald Quinn AM from Griffith University’s Eskitis Institute for Drug Discovery (Brisbane, Australia), reported that testing the new process on a marine sponge had delivered not only validation that the system is successful, but also a potential lead in the fight against Parkinson’s disease. “We have found a new screening method which allows us to identify novel molecules drawn from nature to test for biological activity,” Prof. Quinn said. “As it happens, the first new compound we discovered through this process has demonstrated a response in Parkinson’s disease cells.” 

The findings were published online April 15, 2014, in the chemistry journal Angewandte Chemie. The first author Dr. Tanja Grkovic said the screening process involves nuclear magnetic resonance (NMR) spectroscopy; a highly sensitive instrument through which it is possible to see natural products weighing as little as 20 micrograms. “When you are searching for nature-derived molecules, the jackpot is finding something that nobody has ever seen before and rather than just a variation on a known theme,” Dr. Grkovic said. “We began the project by selecting 20 marine sponge samples randomly from Griffith’s Nature Bank facility and using the NMR technique trying to visualize all the small molecules which could meet the requirements for a potential new drug. “The idea was to look at patterns of data and identify unusual or unique sets. We followed one such pattern and isolated a natural product with a novel skeleton which has turned out to be a molecule which was completely unknown previously.” 

Griffith’s Nature Bank is a novel drug discovery resource based on natural products found in China, Australia, and Papua New Guinea. It comprises more than 45,000 samples of plants and marine invertebrates, 200,000 semipurified fractions, 3,250 pure compounds and over 600 naturally occurring fragments. 

This NMR screening process provides a new way of searching all those natural samples stored in Nature Bank and uncovering the potential biological activity of the compounds within them. 

Deputy director of the Eskitis Institute and coauthor of the paper, Assoc. Prof. George Mellick, is a specialist researcher in neurodegenerative diseases such as Parkinson’s disease. He is excitied by the research prospects this new molecule may provide. “What is very intriguing about this novel natural product is that, while we have found it has an effect on cells sourced from a Parkinson’s patient, it showed a different biological activity on cells from healthy individuals,” Assoc. Prof. Mellick said. “This provides us with a new tool to study the fundamental biology of Parkinson's and to get a better understanding of the cellular processes involved in the development of this disease.” 

The Parkinson’s response is only the beginning, according to the scientists. “This new research technique opens the door to unlimited opportunities, both in terms of chemistry and biology research at Eskitis, as we continue the search for new therapies against disease,” Prof. Quinn said.

Related Links:

Griffith University’s Eskitis Institute for Drug Discovery
 


Channels

Genomics/Proteomics

view channel
Image: Researchers have generated disease-free stem cells from patients with mitochondrial disease that can be converted into any cell type including neuronal progenitors (left) or heart cells (right). These could potentially be used for future transplantation into patients (Photo courtesy of Salk Institute of Biological Studies).

Methods Developed to Generate Normal Stem Cells from Patients with Mitochondrial Defects

A recent paper described two methods for converting cells from patients with mitochondrial defects into normal pluripotent stem cells that could be induced to differentiate into several different types of tissues.... Read more

Drug Discovery

view channel
Image: A new micelle delivery system for the protective polyphenols resveratrol and quercetin (mRQ) may have value in cancer chemotherapy (Photo courtesy of Oregon State University).

Micelles Containing Resveratrol and Quercetin Reverse Doxorubicin Cardiotoxicity

Cancer researchers blocked the toxic effects of the cancer drug doxorubicin (DOX) by administering it together with the plant antioxidants resveratrol and quercetin. Although in use for more than 40... Read more

Business

view channel

Teva Buys Allergan Generic Business Unit

Teva Pharmaceutical Industries (Petah Tikva, Israel) has bought the Allergan (Irvine, CA, USA) generic drugs business for USD 40.5 billion in cash and stock, solidifying its position as the world's largest generic drug maker. Under the terms of the agreement, Teva will pay USD 33.75 billion in cash and USD 6.... Read more
 
Copyright © 2000-2015 Globetech Media. All rights reserved.